Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00702403 · OUTCOME

Survival

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML · Source last updated 2017-08-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 3 years

What was measured

The proportion of study participants alive at 1, 2 and 3 years

Analysis population: Overall Survival (complete follow-up is available out to three years for all patients)

Groups in this outcome

Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)

Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO once daily until day 80 and then nilotinib PO twice daily on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO twice daily beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity. nilotinib: Given PO imatinib mesylate: Given PO pharmacological study: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)40

Reported measurements

Overall Survival at 1 year
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)31Not reportedNot reportedNot reportedNot reported
Overal Survival at 2 years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)28Not reportedNot reportedNot reportedNot reported
Overall Survival at 3 years
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)28Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        31
    title
    Overall Survival at 1 year
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        28
    title
    Overal Survival at 2 years
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        28
    title
    Overall Survival at 3 years
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
description
The proportion of study participants alive at 1, 2 and 3 years
groups
  1. description
    Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO once daily until day 80 and then nilotinib PO twice daily on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO twice daily beginning after engraftment and blood count recovery until day 445. Treatment continues in the absence of disease progression or unacceptable toxicity. nilotinib: Given PO imatinib mesylate: Given PO pharmacological study: Correlative studies
    id
    OG000
    title
    Treatment (Prophylactic Inhibition of BCR-ABL Tyrosine Kinase)
param Type
COUNT_OF_PARTICIPANTS
population Description
Overall Survival (complete follow-up is available out to three years for all patients)
reporting Status
POSTED
time Frame
Up to 3 years
title
Survival
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice